Pediatr Gastroenterol Hepatol Nutr.  2016 Sep;19(3):175-185. 10.5223/pghn.2016.19.3.175.

Henoch-Schonlein Purpura in Children Hospitalized at a Tertiary Hospital during 2004-2015 in Korea: Epidemiology and Clinical Management

• Lee YH
• Kim YB
• Koo JW
• Chung JY

• KMID: 2364776
• DOI: http://doi.org/10.5223/pghn.2016.19.3.175

Abstract

PURPOSE
To investigate the epidemiology, clinical manifestations, investigations and management, and prognosis of patients with Henoch-Schonlein purpura (HSP).
METHODS
We performed a retrospective review of 212 HSP patients under the age of 18 years who were admitted to Inje University Sanggye Paik Hospital between 2004 and 2015.
RESULTS
The mean age of the HSP patients was 6.93 years, and the ratio of boys to girls was 1.23:1. HSP occurred most frequently in the winter (33.0%) and least frequently in the summer (11.3%). Palpable purpura spots were found in 208 patients (98.1%), and gastrointestinal (GI) and joint symptoms were observed in 159 (75.0%) and 148 (69.8%) patients, respectively. There were 57 patients (26.9%) with renal involvement and 10 patients (4.7%) with nephrotic syndrome. The incidence of renal involvement and nephrotic syndrome was significantly higher in patients with severe GI symptoms and in those over 7 years old. The majority of patients (88.7%) were treated with steroids. There was no significant difference in the incidence of renal involvement or nephrotic syndrome among patients receiving different doses of steroids.
CONCLUSION
In this study, the epidemiologic features of HSP in children were similar to those described in previous studies, but GI and joint symptoms manifested more frequently. It is essential to carefully monitor renal involvement and progression to chronic renal disease in patients ≥7 years old and in patients affected by severe GI symptoms. It can be assumed that there is no direct association between early doses of steroids and prognosis.

Keyword

Purpura; Schonlein-Henoch; Child; Nephritis; Prognosis; Signs and symptoms; digestive

MeSH Terms

Child*
Epidemiology*
Female
Humans
Incidence
Joints
Korea*
Nephritis
Nephrotic Syndrome
Prognosis
Purpura
Purpura, Schoenlein-Henoch*
Renal Insufficiency, Chronic
Retrospective Studies
Steroids
Tertiary Care Centers*
Steroids

Reference

1. Saulsbury FT. Henoch-Schönlein purpura. Curr Opin Rheumatol. 2001; 13:35–40.

2. Rostoker G. Schönlein-Henoch purpura in children and adults: diagnosis, pathophysiology and management. BioDrugs. 2001; 15:99–138.

3. Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein purpura [ISRCTN85109383]. BMC Med. 2004; 2:7.

4. Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, et al. Early prednisone therapy in henoch-schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006; 149:241–247.

5. Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics. 2007; 120:1079–1087.

6. Calvo-Río V, Loricera J, Mata C, Martín L, Ortiz-Sanjuán F, Alvarez L, et al. Henoch-Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center. Medicine (Baltimore). 2014; 93:106–113.

7. Lu S, Liu D, Xiao J, Yuan W, Wang X, Zhang X, et al. Comparison between adults and children with Henoch-Schönlein purpura nephritis. Pediatr Nephrol. 2015; 30:791–796.

8. Shin JI, Park JM, Shin YH, Hwang DH, Kim JH, Lee JS. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schönlein purpura. Scand J Rheumatol. 2006; 35:56–60.

9. Hong JH, Na HJ, Namgung MG, Choe SO, Han BG, Jeong SH, et al. Different clinical courses of Henoch-Schönlein purpura in children, adolescents and adults. Korean J Pediatr. 2005; 48:1244–1251.

10. Cohen N, Mimouni FB, Friedel N, Amarilyo G. Predictors of hospital length of stay in pediatric Henoch-Schönlein purpura. Rheumatol Int. 2015; 35:1561–1564.

11. Oh JM, Park JH. Clinical features of Henoch-Schonlein purpura gastroenteropathy without purpura before diagnosis. Korean J Pediatr Gastroenterol Nutr. 2004; 7:54–60.

12. Yang HR, Choi WJ, Ko JS, Seo JK. Intravenous immunoglobulin for severe gastrointestinal manifestation of Henoch-Schönlein purpura refractory to corticosteroid therapy. Korean J Pediatr. 2006; 49:784–789.

13. Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, et al. Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial. Pediatr Nephrol. 2011; 26:2159–2166.

14. Kawasaki Y, Suzuki J, Murai M, Takahashi A, Isome M, Nozawa R, et al. Plasmapheresis therapy for rapidly progressive Henoch-Schönlein nephritis. Pediatr Nephrol. 2004; 19:920–923.

15. Park JM, Won SC, Shin JI, Yim H, Pai KS. Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol. 2011; 26:411–417.

16. Cherqaoui B, Chausset A, Stephan JL, Merlin E. Intravenous immunoglobulins for severe gastrointestinal involvement in pediatric Henoch-Schönlein purpura: a French retrospective study. Arch Pediatr. 2016; 23:584–590.

17. Başaran Ö, Cakar N, Uncu N, Çelikel BA, Kara A, Cayci FS, et al. Plasma exchange therapy for severe gastrointestinal involvement of Henoch Schönlein purpura in children. Clin Exp Rheumatol. 2015; 33:S176–S180.

18. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The american college of rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum. 1990; 33:1114–1121.

19. Saulsbury FT. Henoch-Schönlein purpura in children Report of 100 patients and review of the literature. Medicine (Baltimore). 1999; 78:395–409.

20. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, et al. Clinical course of extrarenal symptoms in Henoch-Schönlein purpura: a 6-month prospective study. Arch Dis Child. 2010; 95:871–876.

21. Weiss PF, Klink AJ, Localio R, Hall M, Hexem K, Burnham JM, et al. Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura. Pediatrics. 2010; 126:674–681.

22. Masarweh K, Horovitz Y, Avital A, Spiegel R. Establishing hospital admission criteria of pediatric Henoch-Schonlein purpura. Rheumatol Int. 2014; 34:1497–1503.

23. Choi SM, Lee KY. Clinico-epidemiologic study of Henoch-Schonlein purpura in children, 1987 through 2003. Korean J Pediatr. 2005; 48:174–177.

24. Zhao YL, Liu ZJ, Bai XM, Wang YC, Li GH, Yan XY. Obesity increases the risk of renal involvement in children with Henoch-Schönlein purpura. Eur J Pediatr. 2015; 174:1357–1363.

25. Anil M, Aksu N, Kara OD, Bal A, Anil AB, Yavaşcan O, et al. Henoch-Schönlein purpura in children from western Turkey: a retrospective analysis of 430 cases. Turk J Pediatr. 2009; 51:429–436.

26. Kang Y, Park JS, Ha YJ, Kang MI, Park HJ, Lee SW, et al. Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schönlein purpura. J Korean Med Sci. 2014; 29:198–203.

27. Hong J, Yang HR. Laboratory markers indicating gastrointestinal involvement of Henoch-Schönlein purpura in children. Pediatr Gastroenterol Hepatol Nutr. 2015; 18:39–47.

28. Nagamori T, Oka H, Koyano S, Takahashi H, Oki J, Sato Y, et al. Construction of a scoring system for predicting the risk of severe gastrointestinal involvement in Henoch-Schönlein purpura. Springerplus. 2014; 3:171.

29. Sano H, Izumida M, Shimizu H, Ogawa Y. Risk factors of renal involvement and significant proteinuria in Henoch-Schönlein purpura. Eur J Pediatr. 2002; 161:196–201.

30. Choi HJ, Cho HY, Kim EJ, Lee BS, Kang HG, Ha IS, et al. Prognostic factors in children with Henoch-Schonlein purpura nephritis. J Korean Soc Pediatr Nephrol. 2005; 9:183–192.

31. Tabel Y, Inanc FC, Dogan DG, Elmas AT. Clinical features of children with Henoch-Schonlein purpura: risk factors associated with renal involvement. Iran J Kidney Dis. 2012; 6:269–274.

32. Wang X, Zhu Y, Gao L, Wei S, Zhen Y, Ma Q. Henoch-Schönlein purpura with joint involvement: analysis of 71 cases. Pediatr Rheumatol Online J. 2016; 14:20.

33. Kim S, Yoon JW, Jeong SJ. Comparison of the clinical manifestations and prognosis of Henoch-Schonlein purpura in children with and without abdominal pain. Korean J Pediatr Gastroenterol Nutr. 2011; 14:359–367.

34. Nam EJ, Kim GW, Kang JW, Im CH, Jeon SW, Cho CM, et al. Gastrointestinal bleeding in adult patients with Henoch-Schönlein purpura. Endoscopy. 2014; 46:981–986.

35. Esaki M, Matsumoto T, Nakamura S, Kawasaki M, Iwai K, Hirakawa K, et al. GI involvement in Henoch-Schönlein purpura. Gastrointest Endosc. 2002; 56:920–923.

36. Park SH, Nam YN, Park SH, Sim SY, Eun BW, Choi DY, et al. Clinical characteristics of childhood Henoch-Schonlein purpura with duodenal involvement by upper gastrointestinal endoscopy. Korean J Pediatr Gastroenterol Nutr. 2009; 12:156–162.

37. Dudley J, Smith G, Llewelyn-Edwards A, Bayliss K, Pike K, Tizard J. Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein purpura (HSP). Arch Dis Child. 2013; 98:756–763.

38. Shin JI, Lee SJ, Lee JS, Kim KH. Intravenous dexamethasone followed by oral prednisolone versus oral prednisolone in the treatment of childhood Henoch-Schönlein purpura. Rheumatol Int. 2011; 31:1429–1432.

39. Deng F, Lu L, Zhang Q, Hu B, Wang SJ, Huang N. Henoch-Schönlein purpura in childhood: treatment and prognosis. Analysis of 425 cases over a 5-year period. Clin Rheumatol. 2010; 29:369–374.

40. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, et al. Outcome of Henoch-Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset. Pediatr Nephrol. 2012; 27:933–939.